Methotrexate chemotherapy promotes osteoclast formation in the long bone of rats via increased pro-inflammatory cytokines and enhanced NF-κB activation

American Journal of Pathology

Volumn 181, Issue 1, 2012, Pages 121-129

  King, Tristan J ^a,b,c   Georgiou, Kristen R ^a,b,c   Cool, Johanna C ^c   Scherer, Michaela A ^a,c   Ang, Estabelle S M ^d   Foster, Bruce K ^c   Xu, Jiake ^d   Xian, Cory J ^a,b,c  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; MESSENGER RNA; METHOTREXATE; OSTEOPROTEGERIN; PARTHENOLIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE MARROW EXAMINATION; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; METAPHYSIS; NONHUMAN; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CYTOKINES; GENE EXPRESSION REGULATION; INFLAMMATION MEDIATORS; MALE; METHOTREXATE; NF-KAPPA B; OSTEOCLASTS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862680801     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2012.03.037     Document Type: Article

References (50)

1. Davies JH, Evans BA, Gregory JW: Bone mass acquisition in healthy children. Arch Dis Child 2005, 90:373-378
2. Arikoski P, Komulainen J, Riikonen P, Parviainen M, Jurvelin JS, Voutilainen R, Kroger H: Impaired development of bone mineral density during chemotherapy: a prospective analysis of 46 children newly diagnosed with cancer. J Bone Miner Res 1999, 14:2002-2009
3. Gnudi S, Butturini L, Ripamonti C, Avella M, Bacci G: The effects of methotrexate (MTX) on bone: a densitometric study conducted on 59 patients with MTX administered at different doses. Ital J Orthop Traumatol 1988, 14:227-231
4. Halton JM, Atkinson SA, Fraher L, Webber C, Gill GJ, Dawson S, Barr RD: Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia. J Bone Miner Res 1996, 11:1774-1783
5. Hadji P, Ziller M, Maskow C, Albert U, Kalder M: The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer. Eur J Cancer 2009, 45:3205-3212
6. Pfeilschifter J, Diel IJ: Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000, 18:1570-1593
7. Mandel K, Atkinson S, Barr RD, Pencharz P: Skeletal morbidity in childhood acute lymphoblastic leukemia. J Clin Oncol 2004, 22:1215-1221
8. Cegiela U, Sliwinski L, Kaczmarczyk-Sedlak I, Folwarczna J: In vivo effects of high-dose methotrexate on bone remodeling in rats. Pharmacol Rep 2005, 57:504-514
9. Friedlaender GE, Tross RB, Doganis AC, Kirkwood JM, Baron R: Effects of chemotherapeutic agents on bone, I: short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model. J Bone Joint Surg Am 1984, 66:602-607
10. May KP, West SG, McDermott MT, Huffer WE: The effect of low-dose methotrexate on bone metabolism and histomorphometry in rats. Arthritis Rheum 1994, 37:201-206
11. Wheeler DL, Vander Griend RA, Wronski TJ, Miller GJ, Keith EE, Graves JE: The short- and long-term effects of methotrexate on the rat skeleton. Bone 1995, 16:215-221
12. Nilsson OS, Bauer FC, Brostrom LA, Nilsonne U: Effect of the antineoplastic agent methotrexate on experimental heterotopic new bone formation in rats. Cancer Res 1984, 44:1653-1656
13. Halton JM, Atkinson SA, Fraher L, Webber CE, Cockshott WP, Tam C, Barr RD: Mineral homeostasis and bone mass at diagnosis in children with acute lymphoblastic leukemia. J Pediatr 1995, 126:557-564
14. Elliot KJ, Millward-Sadler SJ, Wright MO, Robb JE, Wallace WH, Salter DM: Effects of methotrexate on human bone cell responses to mechanical stimulation. Rheumatology (Oxford) 2004, 43:1226-1231
15. Fan C, Cool JC, Scherer MA, Foster BK, Shandala T, Tapp H, Xian CJ: Damaging effects of chronic low-dose methotrexate usage on primary bone formation in young rats and potential protective effects of folinic acid supplementary treatment. Bone 2009, 44:61-70
16. Xian CJ, Cool JC, Scherer MA, Macsai CE, Fan C, Covino M, Foster BK: Cellular mechanisms for methotrexate chemotherapy-induced bone growth defects. Bone 2007, 41:842-850
17. Crofton PM, Ahmed SF, Wade JC, Stephen R, Elmlinger MW, Ranke MB, Kelnar CJ, Wallace WH: Effects of intensive chemotherapy on bone and collagen turnover and the growth hormone axis in children with acute lymphoblastic leukemia. J Clin Endocrinol Metab 1998, 83:3121-3129
18. Boyle WJ, Simonet WS, Lacey DL: Osteoclast differentiation and activation. Nature 2003, 423:337-342
19. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323
20. Blair HC, Robinson LJ, Zaidi M: Osteoclast signalling pathways. Biochem Biophys Res Commun 2005, 328:728-738
21. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL: IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005, 115:282-290
22. Goldring SR: Inflammatory mediators as essential elements in bone remodeling. Calcif Tissue Int 2003, 73:97-100
23. Tanaka Y, Nakayamada S, Okada Y: Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr Drug Targets Inflamm Allergy 2005, 4:325-328
24. Xing L, Bushnell TP, Carlson L, Tai Z, Tondravi M, Siebenlist U, Young F, Boyce BF: NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J Bone Miner Res 2002, 17:1200-1210
25. Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, Leonardi A, Tran T, Boyce BF, Siebenlist U: Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 1997, 11:3482-3496
26. Humphrey MB, Ogasawara K, Yao W, Spusta SC, Daws MR, Lane NE, Lanier LL, Nakamura MC: The signaling adapter protein DAP12 regulates multinucleation during osteoclast development. J Bone Miner Res 2004, 19:224-234
27. Nakano Y, Toyosawa S, Takano Y: Eccentric localization of osteocytes expressing enzymatic activities, protein, and mRNA signals for type 5 tartrate-resistant acid phosphatase (TRAP). J Histochem Cytochem 2004, 52:1475-1482
28. Zhou FH, Foster BK, Zhou XF, Cowin AJ, Xian CJ: TNF-alpha mediates p38 MAP kinase activation and negatively regulates bone formation at the injured growth plate in rats. J Bone Miner Res 2006, 21:1075-1088
29. Ominsky MS, Li X, Asuncion FJ, Barrero M, Warmington KS, Dwyer D, Stolina M, Geng Z, Grisanti M, Tan HL, Corbin T, McCabe J, Simonet WS, Ke HZ, Kostenuik PJ: RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. J Bone Miner Res 2008, 23:672-682
30. Xu J, Tan JW, Huang L, Gao XH, Laird R, Liu D, Wysocki S, Zheng MH: Cloning, sequencing, and functional characterization of the rat homologue of receptor activator of NF-kappaB ligand. J Bone Miner Res 2000, 15:2178-2186
31. Stolina M, Adamu S, Ominsky M, Dwyer D, Asuncion F, Geng Z, Middleton S, Brown H, Pretorius J, Schett G, Bolon B, Feige U, Zack D, Kostenuik PJ: RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J Bone Miner Res 2005, 20:1756-1765
32. Wang C, Steer JH, Joyce DA, Yip KH, Zheng MH, Xu J: 12-O- tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation. J Bone Miner Res 2003, 18:2159-2168
33. Yip KH, Zheng MH, Feng HT, Steer JH, Joyce DA, Xu J: Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity. J Bone Miner Res 2004, 19:1905-1916
34. Georgiou KR, Scherer MA, Fan CM, Cool JC, King TJ, Foster BK, Xian CJ: Methotrexate chemotherapy reduces osteogenesis but increases adipogenesis potential in the bone marrow. J Cell Physiol 2012, 227:909-918
35. Fan C, Foster BK, Wallace WH, Xian CJ: Pathobiology and prevention of cancer chemotherapy-induced bone growth arrest, bone loss, and osteonecrosis. Curr Mol Med 2011, 11:140-151
36. Fan C, Georgiou KR, King TJ, Xian CJ: Methotrexate toxicity in growing long bones of young rats: a model for studying cancer chemotherapy-induced bone growth defects in children. J Biomed Biotechnol 2011, 2011:903097
37. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, Suda T: Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000, 191:275-286
38. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, Steiner G, Smolen JS, Wagner EF, Schett G: Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002, 110:1419-1427
39. Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson DM, Suda T: Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 1999, 190:1741-1754
40. Miyamoto T, Suda T: Differentiation and function of osteoclasts. Keio J Med 2003, 52:1-7
41. Yao Z, Li P, Zhang Q, Schwarz EM, Keng P, Arbini A, Boyce BF, Xing L: Tumor necrosis factor-alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression. J Biol Chem 2006, 281:11846-11855
42. Li P, Schwarz EM, O'Keefe RJ, Ma L, Boyce BF, Xing L: RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. J Bone Miner Res 2004, 19:207-213
43. Villani F, Viola G, Vismara C, Laffranchi A, Di Russo A, Viviani S, Bonfante V: Lung function and serum concentrations of different cytokines in patients submitted to radiotherapy and intermediate/high dose chemotherapy for Hodgkin's disease. Anticancer Res 2002, 22:2403-2408
44. Kawagishi C, Kurosaka K, Watanabe N, Kobayashi Y: Cytokine production by macrophages in association with phagocytosis of etoposide-treated P388 cells in vitro and in vivo. Biochim Biophys Acta 2001, 1541:221-230
45. Rossa C, Ehmann K, Liu M, Patil C, Kirkwood KL: MKK3/6-p38 MAPK signaling is required for IL-1beta and TNF-alpha-induced RANKL expression in bone marrow stromal cells. J Interferon Cytokine Res 2006, 26:719-729
46. Sato T, Morita I, Sakaguchi K, Nakahama KI, Smith WL, Dewitt DL, Murota SI: Involvement of prostaglandin endoperoxide H synthase-2 in osteoclast-like cell formation induced by interleukin-1 beta. J Bone Miner Res 1996, 11:392-400
47. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S: Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999, 25:255-259
48. Xu J, Wu HF, Ang ES, Yip K, Woloszyn M, Zheng MH, Tan RX: NF-kappaB modulators in osteolytic bone diseases. Cytokine Growth Factor Rev 2009, 20:7-17
49. Hehner SP, Hofmann TG, Droge W, Schmitz ML: The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex. J Immunol 1999, 163:5617-5623
50. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL: TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000, 106:1481-1488